Efficient TAVI in the context of expanding indications?

Sponsored by Medtronic

Speakers: L. Sondergaard, D. Tchetche

Summary

Watch this session presented by Lars Sondergaard and Didier Tchetche in order to review latest data from the Evolut low-risk trial and the OptimizePro study, to learn more about latest TAVI patient pathway efficiency and economics evidence, and to discover how to translate these insights locally and enable you to treat more patients.

Learning Objectives

To review latest data from the Evolut low-risk trial and the OptimizePro study
To learn more about latest TAVI patient pathway efficiency and economics evidence
To discover how to translate these insights locally and enable you to treat more patients